Biopharmaceutical Analysis

Mark Rogers, PhD, mark.rogers@sgs.com, is the global scientific director for the SGS Health Science Drug Development group. He  has been with SGS for nearly 8 years since joining the company via an acquisition (M-Scan) in 2010. Rogers received his PhD in analytical chemistry from Westminster University in 1985 and has over 35 peer-reviewed publications, including Nature, and one patent. His post-doctoral work, at Imperial College, London, was followed by a lectureship in the endocrinology department at St. Mary’s hospital specializing in diabetes. Rogers then went on to join M-Scan, USA in 1990 where he remained as vice-president until its acquisition by SGS. Since joining SGS he has had several roles including, head of North American Biologics, vice-president of SGS USA, and today, he is the Global Scientific director for the SGS Health Science Drug Development group.

Articles

Considerable efforts have been made over the years to resolve the key issues of stability and delivery of RNA-based therapeutics.

The Marriage of RNA and Mass Spectrometry

is chief scientific officer and distinguished scientist at InterVenn BioSciences.

Assessment of peripheral blood protein glycosylation has recently become scalable, providing a new domain for biomarker research. 

A New Era of Biomarker Discovery: Harnessing the Clinical Power of AI-Driven Glycoproteomics 

Chris Spivey is the editorial director of 

Fresh insight is instrumental in the discussion of novel analytics.

Dual Modality and New Analyses

Thermo Fisher and Symphogen have extended their collaboration involving improved data workflow, which supports the discovery and development of new cancer treatments.

Thermo Fisher Scientific Extends Collaboration Support for Biopharma Discovery and Development

A new portfolio of chromatography and mass spectrometry consumables launched by Thermo Fisher Scientific is designed to meet higher performance requirements while remaining economical.

Thermo Fisher Scientific Introduces New Portfolio of Chromatography and Mass Spectrometry Consumables

Peter Zipfell is product marketing manager, CDS Software, at Thermo Fisher Scientific.

Michelle English is Data Science product manager at Protein Metrics.

The integration of modern software tools can make the acquisition and analysis of MS data more efficient, accurate, and compliant.

Connected Software Solutions Streamline Biopharma MS Workflows

Prashant Pokhriyal is associate scientist at Intas Pharmaceuticals Ltd. (Biopharma Division), Ahmedabad, Gujarat, India.

Prateek Gupta is senior general manager at Intas Pharmaceuticals Ltd. (Biopharma Division), Ahmedabad, Gujarat, India.

Sridevi Khambhampaty is vice-president at Intas Pharmaceuticals Ltd. (Biopharma Division), Ahmedabad, Gujarat, India.

Rajesh Ullanat is executive vice-president at Intas Pharmaceuticals Ltd. (Biopharma Division), Ahmedabad, Gujarat, India.

Mili Pathak is principal scientist, Process Science, R&D, at Intas Pharmaceuticals Ltd. (Biopharma Division), Ahmedabad, Gujarat, India.

Modeling techniques can improve process control and monitoring in biopharmaceutical production.

Recent Trends in Data Analytics for Upstream Process Workflows

Thermo Fisher Scientific showcases its new mass spectrometry and chromatography solutions at the ASMS Conference on Oct. 31–Nov. 4, 2021. 

Thermo Fisher Launches New Mass Spectrometry and Chromatography Solutions

CuriRx’s CuriLytics platform is a mass spectrometry instrument that will support complex biotherapeutics development.

CuriRx Launches CuriLytics Platform

Olaf Stamm, PhD, is scientific advisor, biologics testing with Charles River.

Andrew Hanneman, PhD, is scientific advisor, biologics testing with Charles River.

Art Cansizoglu, PhD, is senior scientist with Charles River.

Thorsten Strahl is supervisor protein and scientific officer with Charles River.

Gene therapy products present a unique set of challenges for the control of host cell protein impurities.

Biopharmaceutical Analysis: Mass Spectrometry